A Randomized, Open Label, Active-Controlled, 4-Treatment, 2-Period, 2 Parallel Block Crossover Pharmacokinetic and Safety Study of 2 Doses of MAP0010 [budesonide] in Adult Asthmatics

Trial Profile

A Randomized, Open Label, Active-Controlled, 4-Treatment, 2-Period, 2 Parallel Block Crossover Pharmacokinetic and Safety Study of 2 Doses of MAP0010 [budesonide] in Adult Asthmatics

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2014

At a glance

  • Drugs Budesonide (Primary)
  • Indications Asthma
  • Focus Pharmacokinetics
  • Sponsors MAP Pharmaceuticals
  • Most Recent Events

    • 03 May 2008 Status changed from in progress to completed.
    • 03 Apr 2008 Results have been reported by MAP Pharmaceuticals.
    • 10 Dec 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top